BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

BridgeBio Pharma (BBIO) has granted equity awards to 36 new employees in the form of restricted stock units totaling 101,974 shares of common stock. The grants were approved by the compensation committee on May 9, 2025. The vesting schedule includes 25% of shares vesting on May 16, 2026, followed by quarterly vesting of the remaining shares in one-twelfth increments, contingent on continued employment. These inducement grants were made under BridgeBio's Amended and Restated 2019 Inducement Equity Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).

PALO ALTO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on May 9, 2025, the compensation committee of BridgeBio’s board of directors approved equity grants to 36 new employees in restricted stock units for an aggregate of 101,974 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on May 16, 2026, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio’s Amended and Restated 2019 Inducement Equity Plan (the “Plan”).

The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.

About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers, and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, and YouTube.

BridgeBio Media Contact:
Bubba Murarka, EVP Communications
contact@bridgebio.com
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, VP IR & Strategic Finance
Chinmay.shukla@bridgebio.com

FAQ

How many shares were granted in BridgeBio's (BBIO) May 2025 inducement grants?

BridgeBio granted restricted stock units for an aggregate of 101,974 shares of common stock to 36 new employees.

What is the vesting schedule for BBIO's May 2025 restricted stock unit grants?

25% of shares vest on May 16, 2026, with the remaining shares vesting quarterly in one-twelfth increments, subject to continued employment.

Under which plan were BridgeBio's May 2025 inducement grants made?

The grants were made under BridgeBio's Amended and Restated 2019 Inducement Equity Plan, which was last amended on December 13, 2023.

Why did BridgeBio (BBIO) issue these equity grants in May 2025?

The equity grants were issued as inducement material to new employees entering into employment with BridgeBio, in accordance with Nasdaq Listing Rule 5635(c)(4).